For the application of RNA interference (RNAi) in vivo the functional delivery of short interfering RNAs (siRNAs) is still the major obstacle. Therefore, delivery technologies need to be established for the systemic application of RNAi in vivo.
Introduction
In a first step towards the development of short interfering RNA (siRNA) therapeutics, we and others have improved the stability of siRNA molecules by incorporating different chemical backbone modifications preventing these molecules from degradation by nucleases. [1] [2] [3] [4] For example, blunt-ended siRNA molecules were developed with alternating 2 0 -O-methyl modification patterns on both strands, which are significantly more resistant to plasma-derived nucleases than unmodified siRNAs, and are just as much capable of gene expression silencing in mammalian cells after transfection. 2 Above and beyond the stability issue, functional delivery of siRNA molecules in vivo is still the major obstacle and a prerequisite for the development of siRNA therapeutics. 5 Several recent reports have shown local delivery of siRNAs in vivo, including local administration to the eye for the treatment of age-related macular degeneration, 6, 7 intranasal administration for pulmonary delivery [8] [9] [10] [11] and direct delivery into the central nervous system. 12 Despite these promising results on local delivery, an effective, non-toxic systemic application of siRNA-based therapeutics has not yet been developed for clinical application due to the absence of appropriate non-viral delivery technologies.
These technologies need to address several problems including the functional intracellular uptake of the highly negatively charged siRNAs, the pharmacodynamic properties for organ and cell type specific in vivo delivery, and finally the potential toxic side effects through formulation of siRNA. One strategy extensively tested for in vivo delivery of antisense oligonucleotides to overcome these problems is the direct chemical alteration of the nucleic acid. These chemical modifications are either backbone modifications 4 or conjugates with uptake-mediating entities such as transporting peptides [13] [14] [15] [16] or hydrophobic residues (e.g. cholesterol 3 ). Several reagents have been employed for systemic intravenous (i.v.) administration of siRNAs in mice as an alternative to the covalent modifications of siRNAs. Positively charged carriers, such as protamine-antibody fusion proteins, nanoparticles, cyclodextrin-containing polycation, PEI and atelocollagen have been tested for complex formation with siRNAs for applications in vivo. [17] [18] [19] [20] [21] [22] [23] In order to achieve more cell-type-specific delivery of siRNAs, some groups have incorporated or conjugated receptor-ligands 22 or antibodies for cellular targeting. 23 Cationic lipids are routinely used for delivery of nucleic acids into mammalian cells in vitro, 24 and systemic i.v. administration of lipoplexes (composed of cationic lipid, neutral helper lipid and nucleic acid) have been applied for gene and siRNA delivery in vivo. 4, 21, [25] [26] [27] [28] [29] However, most of the previous studies were designed for proof of concept but do not provide information on the pharmacodynamic behavior and possible toxicity of the applied siRNA formulation. This information is a prerequisite for further clinical development with regards to a right risk-benefit assessment of the particular delivery technology. For example, bioavailability, cell-type-specific delivery and in vivo pharmacokinetics (depending on the routes of administration: i.v., subcutaneous, oral) are important parameters to evaluate in addition to the demonstration of in vivo gene silencing efficacy. Although a large number of previous studies report the in vivo properties of various modified antisense oligonucleotides (Geary et al. 30 and references therein), only little is known about the pharmacodynamic behavior of non-formulated or formulated siRNA and its chemically modified analogues in vivo. Intravenous injection of chemically modified siRNAs resulted in a broad tissue distribution with accumulation preferentially in the liver, jejunum and kidney. 3, 31 In another study, radioactively labeled siRNA was predominantly detected in muscle and tumor tissue of xenografted mice, and little in the liver and kidney when administered intraperitoneally (i.p.) as PEI complex. 20 However, these studies did not discriminate the delivery to the many different cell types present in each organ.
Here, we report the development of novel siRNA formulations for the systemic in vivo application of siRNAs. We characterized these siRNA-lipoplexes in vitro and determined the biodistribution after i.v. application in mice. In contrast to naked or nonformulated siRNA molecules, the siRNA-lipoplexes were strongly taken up by the vascular endothelium in the liver, heart and lung. The observed organ distribution was correlated with RNA interference (RNAi) efficacy by means of knockdown analysis for two endogenous gene targets, namely Tie2 and CD31. A repeated systemic i.v. administration of target-specific siRNA-lipoplexes resulted in a clear knockdown of mRNA as well as protein of these endothelium-specifically expressed target genes demonstrating the functional uptake and RNAimediated silencing activity.
Results

Characterization of siRNA-lipoplexes in vitro
We have employed 19-mer siRNA duplexes lacking 3 0 -overhangs, which are chemically stabilized by alternating 2 0 -O-methyl sugar modifications on both strands, 2 whereby unmodified nucleotides face modified ones on the opposite strand (Table 1) . It has been demonstrated previously in cell culture (ex vivo) 2 that these particularly modified molecules enhance resistance towards serum nuclease, while RNAi activity is preserved. First we analyzed whether these molecules mediate RNAi in cell culture either complexed with cationic liposomes or without formulation ('naked'). For this purpose, we synthesized a newly designed cationic lipid, referred to as AtuFECT01, in combination with commercially available helper lipids (Figure 1a ). This novel lipid is characterized by a highly charged head group, which allows for more efficient siRNA-binding as compared to other commercially available cationic lipids such as DOTAP or DOTMA. In the following study, we used siRNA-lipoplexes consisting of positively charged liposomes (50 mol% cationic lipid AtuFECT01, 49 mol% neutral/helper lipid 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPhyPE), and 1 mol% distearoylsn-glycero-3-phospho-ethanolamine sodium salt (DSPE-PEG)) in combination with different target-specific siRNA molecules (for lipoplex preparation, see Materials and methods). The liposomes and the siRNA-lipoplexes were characterized regarding size and charge by QELS and zeta-potential measurement (Figure 1 ). Immunoblot analysis demonstrated that no gene silencing occurred when naked siRNA was applied at even micromolar concentrations compared to nanomolar concentrations used for siRNA-lipoplexes (Figure 2a ). To analyze whether the lack of gene silencing was the result of an inefficient cellular uptake because of repulsive effects between the anionic siRNAs and the negatively charged cell membrane, we employed 3 0 fluorescently (Cy3) labeled siRNAs to study their uptake by confocal microscopy. We and others have previously shown that fluorescence labeling at the 3 0 -end of the antisense molecule does not impair RNA silencing activity when transfected with delivery vehicles. 2, 32 Surprisingly, we observed a significant uptake of fluorescently labeled siRNAs in the absence of transfection reagents when high concentrations (10 mM) of siRNA-Cy3 molecules were applied (Figure 2b ). In contrast, equivalent siRNA-Cy3 uptake was achieved when transfected with AtuFECT01 at a thousand-fold lower siRNA-Cy3 concentration (10 nM). However, the majority of the fluorescent label appeared to become trapped in late endosomal/lysosomal vesicles as demonstrated by colocalization with the LysoTracker marker. This suggests that unformulated siRNAs remain trapped in the endosomal pathway (Figure 2c, upper panel) . In contrast, fluorescently labeled siRNA-Cy3 transfected as lipoplexes did not fully colocalize with Lysotracker, but appeared to escape the late endosomal/lysosomal vesicles ( Figure 2c , lower panel). These results indicate that siRNA-lipoplexes provide at least two beneficial effects for functional delivery of siRNAs: an improved cellular uptake and more importantly, the escape from the endocytotic/endosomal pathway into the cytoplasm, 33 where RNAi-mediated mRNA degradation takes place. Figure 3e ). Therefore, it seems unlikely that an unspecific cytokine response caused the observed body weight reduction upon non-PEGylated siRNA-lipoplex treatment. Taken together, these data show that 1 mol% of DSPE-PEG-2000 in the siRNA-lipoplex formulations is sufficient to reduce unspecific toxic side effects in vivo without a severe loss in RNAi efficacy in vitro. Consequently, a defined degree of PEGylation appears to be an important prerequisite for a safe and efficient in vivo application of the here characterized siRNA-lipoplexes.
Specific uptake of lipoplexed short interfering RNA into the vascular endothelium and renal excretion of naked short interfering RNA In a next step we set out to investigate the biodistribution and kinetics of siRNA-lipoplexes in comparison with non-formulated siRNA after systemic treatment of mice. For this purpose, we injected a single dose of Cy3 fluorescently labeled siRNA either complexed with lipids (200 ml i.v. injection at a final dose of 1.88 mg/kg siRNA-Cy3 and 14.5 mg/kg lipid) or not formulated (siRNA-Cy3: 0.188 mg/ml equal to 15 mM) into immunecompetent mice, and dissected six different organs at nine time points (from 5 min to 48 h) for examination by epifluorescence and confocal microscopy. An initial microscopic analysis revealed that fluorescence was detectable in all tissues analyzed from animals 20 min post-treatment with siRNA-Cy3-lipoplex ( Figure 4a , lower panel). The Cy3-fluorescence appeared in a distinct staining pattern for each organ. This organspecific Cy3-staining pattern is reminiscent of the tissue endothelia distribution as visualized by immunohistological staining of tissue sections for CD31 protein, a marker protein for endothelial cells (Figure 4a , upper row). In contrast, naked siRNA was predominantly found in the kidney 20 min post-injection, with no detectable signals in other organs, suggesting a rapid renal excretion of non-formulated siRNA molecules ( Figure 4a , middle row). In addition the applied, naked siRNA-Cy3 accumulates in the pole and lumen of the proximal tubules and in the urine 5 min after injection, which was not observed for lipoplexed siRNA-Cy3 (data not shown). In conclusion, non-formulated siRNAs were not targeted to any cell type of analyzed tissues in vivo after systemic administration, this being most likely due to instant renal excretion. For the siRNA-Cy3-lipoplexes, the microscopic fluorescence data suggest, however, that The improved siRNA uptake of an organ, however, does not necessarily indicate an intracellular or cell-typespecific uptake of these molecules, which is a prerequisite for the functionality of the delivered siRNAs. A more detailed analysis of formulated siRNA-Cy3 uptake in the heart and lung by confocal microscopy revealed that on the cellular level, fluorescence staining was predominantly present in the linings of the blood vessels suggesting delivery to endothelial cells. The vascular endothelium in the heart was visualized by immunohistochemistry using an anti-CD31 antibody (Figure 4c) . The staining for the CD31 expressing endothelial cells illustrates the presence of numerous blood capillaries along the cardiac muscle cells (Figure 4c ; arrow: cross and longitudinal sections of capillaries). These capillary structures were decorated in the heart from mice treated with a single i.v. injection of siRNA-Cy3-lipoplex as revealed by confocal microscopy (Figure 4c, right panel) . To demonstrate that the fluorescently labeled siRNA-Cy3 molecules are delivered through endothelial targeting of the intact siRNA-lipoplex, we analyzed heart crosssections from mice treated with a single i.v. injection of doubly labeled lipoplexes containing Cy5-labeled siRNA molecules formulated with TexasRed s labeled liposomes (see Materials and methods). The fluorescence microscopy analysis of the doubly labeled siRNA-lipoplexes revealed a co-localization of both components to the heart capillaries ( Figure 4c, lower panels) . This result indicates that lipid and siRNA components are delivered together to the endothelial linings suggesting that the siRNA-lipoplexes are stable in the bloodstream. Confocal microscopy of lung sections from mice treated with siRNA-Cy3-lipoplexes revealed a punctuate staining of the alveolar wall, but not of the bronchiole epithelium (Figure 4d ). The alveolar wall is traversed by the endothelium of the alveolar capillaries as visualized by staining with anti-CD31. We therefore conclude that siRNAs lipoplexed using the here described liposomes become delivered to the capillary endothelium of the lung. A similar endothelial cell-specific siRNA uptake was observed for other organs including the liver, pancreas, kidney, small intestine, stomach (data not shown). Taken together, these data demonstrate that cationic lipid-based formulations of siRNAs improve the biodistribution properties of siRNAs and allow for a predominant uptake of siRNAs into endothelial cells throughout the body. 
siRNA-lipoplex application in vivo
A Santel et al siRNA-lipoplex-mediated RNA interference in the vasculature of the lung, heart and liver Systemic treatment of mice with siRNA-Cy3-lipoplex suggests a delivery of siRNAs to the endothelial compartment of different organs. Following this observation, we then aimed to correlate siRNA uptake and distribution with the efficacy of RNAi in particular organs. For this purpose, we designed the following in vivo experiment: nude mice (6-8 per cohort) were treated with four consecutive daily i.v. injections (daily dose: 1.88 mg/kg siRNA and 14.5 mg/kg lipid) with three target-specific siRNA-lipoplexes. Potent siRNAs specific for the two endogenous gene targets, CD31 (PECAM-1) and Tie2, were identified in vitro and applied to demonstrate RNAi silencing in the vasculature of selected organs. Importantly, the expression of these two genes is highly restricted to endothelial cells. Additional groups of mice were treated in parallel with sucrose solution or with siRNA-lipoplex specific for the murine PTEN coding sequence to control for unspecific effects. PTEN is, in contrast to CD31 and Tie2, ubiquitously expressed in all cell types of the mice. Gene expression was assessed by measuring changes in mRNA levels employing reverse transcription-polymerase chain reaction (RT-PCR) and protein levels by immunoblot and ELISA methods 24 h after the last siRNA-lipoplex treatment ( Figure 5 ). Total RNA was prepared from the lung, heart and liver of corresponding treatment groups (sucrose, siRNA -lipoplex group demonstrates the target specificity of the siRNA treatment. In the liver, the knockdown in mRNA level was more prominent for Tie2 (Figure 5a, lower panel) , whereas in the lung and heart the expression of both target genes were inhibited similarly. To corroborate the siRNA-mediated inhibition of the both target genes, we set out to confirm the inhibition of Tie2 protein expression by immunoblot (Figure 5b ). Organ protein lysates from 6-7 individual animals of the siRNA Tie2 -lipoplex or the siRNA CD31 -lipoplex treatment groups were prepared, separated by sodium dodecyl-polyacrylamide gel electrophoresis (SDS-PAGE), and corresponding immunoblots were probed with anti-Tie2 and anti-PTEN (loading control). A significant reduction of Tie2 protein was observed in all three organs from siRNA Tie2 -lipoplex-treated animals. With protein lysates from the liver we were not able to detect significant amounts of CD31 by immunoblot. However, a significant siRNA CD31 -lipoplex-specific reduction of CD31 protein level was demonstrated for the lung and heart. Taken together, these data demonstrate a siRNA-mediated 'gene silencing' on mRNA and protein level in the vascular endothelium of the mouse.
As the Tie2 protein level was significantly reduced in protein lysates of all three analyzed organs, we analyzed whether we can detect a reduction in the level of the soluble form of Tie2 in the blood of siRNA Tie2 -lipoplextreated animals. The Tie2 protein acts as a receptor tyrosine kinase exclusively in endothelial cells in concert with its ligands, the angiopoietins, thus contributing to vessel remodeling and integrity. 37, 38 The soluble form of Tie2, s-Tie2, is a product of proteolytic cleavage of the receptor's extracellular domain, which can be easily detected in the blood by ELISA assays. We monitored changes in s-Tie2 in the serum before and after siRNAlipoplex treatment using an s-Tie2 ELISA as readout. All four groups of mice tested showed similar levels in s-Tie2 before treatment (day 0; Figure 5c , left diagram). Mice treated with siRNA Tie2 -lipoplex exhibited a significant reduction in s-Tie2 levels when compared to treated mice from control cohorts (sucrose, siRNA PTEN , siRNA
CD31
) on day 5 of the treatment schedule (day 5; Figure 5c , right diagram). This result implies that systemic siRNA Tie2 -lipoplex treatment affects overall Tie2 gene expression in vivo, presumably by suppressing Tie2 protein expression in the body's vasculature endothelium. In conclusion, AtuFECT01-based siRNA-lipoplexes are targeted to the vascular endothelium of many tissues after i.v. administration. Repeated administration of siRNAlipoplexes resulted in mRNA as well as protein knockdown of endothelial gene expression in a target-specific manner in tissues such as the lung, heart, and liver. Interestingly, no suppression of endothelial gene expression is observed in the kidney and spleen (Supplementary Figure S1b ) despite a very apparent siRNA-Cy3 distribution in these two organs. Therefore, the analysis of organ siRNA-uptake, even with consideration of cellular distribution, does not necessarily predict RNAi efficacy.
Discussion
RNA interference can be used for the generation of loss of function phenotypes in gene function analysis, but also has potential for the development of nucleic acidbased therapeutics. The in vivo application of siRNAs for specific targeting disease relevant genes has been limited by several technical obstacles such as stability of the siRNAs in body fluids, functional intracellular uptake, bioavailability and cell-type-specific targeting. Our results advocate the use of cationic lipid-based formulations of siRNA for RNAi applications in vivo. Most in vivo studies with naked siRNAs attempt to circumvent the problem of poor biodistribution by administering high doses directly to the target organ by injection. 6, 8, 9, 12, 21, [39] [40] [41] However, the systemic administration is still the most clinically relevant route for other indications such as cancer or metabolic diseases. Here, we provide evidence that systemically administered lipoplexed siRNAs have better pharmacokinetic properties than non-formulated siRNA molecules that are rapidly excreted through the kidney (Figure 4a , additional data not shown). The application of cationic lipids to deliver nucleic acids in vivo has hitherto been limited by their low efficiency and high systemic toxicity after i.v. administration. [42] [43] [44] siRNA-lipoplex application in vivo A Santel et al
We have developed a novel cationic lipid-based siRNA formulation (Figure 1 ), which can be administered repeatedly into the tail vein of mice in a therapeutic setting. No significant toxicity as indicated by the absence of weight loss or increased levels of AST/ALT enzymes (data not shown) as indicators for liver damage was observed with the administered efficacious daily doses (1.88 mg/kg siRNA, 14.5 mg/kg lipid mixture). The here described non-viral siRNA delivery technology makes use of the nucleic acid complexing properties of the novel cationic lipid (AtuFECT01) in combination with a neutral lipid (also called helper lipid, e.g. DPhyPE), which mediates the endosomal release of the siRNAs after endocytotic uptake of the lipoplex. A smaller amount of lipid is required to complex the siRNA molecules, due to the higher nucleic acid binding capacity of AtuFECT01 (three positive charges per molecule) compared to standard lipids such as DOTAP (one positive charge), and potential lipid-associated toxicity is reduced. Several recent papers have described an unspecific interferon response after administration of lipid-formulated siRNA molecules in mice. [45] [46] [47] However, these published data were generated with different delivery systems such as DOTAP or DOTMA suggesting that DOTAP-based formulations of siRNA are prone to induce interferon response in vivo. In vitro as well as in vivo experiments with the lipoplexes used in this study did not reveal an increase in the expression of the interferon responsive OAS-1 and OAS-2 genes in HeLa cells (data not shown). More importantly, no induction of The biodistribution analysis on systemic administered siRNA-lipoplexes indicated a predominantly specific targeting of endothelial cells in the vasculature of several organs after single dosing. These observations are in accordance with the size distribution of the lipoplex particles (in vitro: 120 nm in average). The particle size might be one determinant for targeting the vascular endothelium as a number of cellular barriers have to be crossed before entering the adjacent parenchymal tissue for any i.v. administered formulated complex. Usually, particles entering from the bloodstream first have to pass through the endothelial cell layer (transcellular transport) before crossing the underlying basal membrane or possibly the pericytes layer. Adjacent endothelial cells are connected with each other via tight and gap junction that do not allow the passage of lipoplexes or other particles larger than 3-5 nm in size (note: even non-formulated siRNAs are already bigger than 5 nm). In contrast, other reports on lipid-formulated siRNAs in vivo describe functional delivery to hepatocytes 4 and tumor cells. 18, 21 It remains to be elucidated in more detail, however, whether smaller particles (below 50 nm) with novel/ different targeting properties can be generated and applied in vivo. Some reports suggest that next to the particle size, the positive charge of cationic lipids significantly contributes to an increased uptake by the endothelial cells of blood vessels in tumor tissues. 48, 49 We have focussed on endothelial cells in vivo in order to correlate the biodistribution as studied by fluorescence microscopy with the cell-type-specific RNAi activity. We chose two target genes CD31 and Tie2, both expressed in endothelial cells only, to analyze gene expression knockdown by means of RT-PCR and immunoblot in different organs. Importantly, a reduction of endogenous CD31 and Tie2 expression was observed in some organs such as the lung, liver and heart of corresponding animals, but with notable difference in terms of efficacy. However, a few organs, such as the kidney and spleen exhibited a strong uptake of fluorescently labeled lipoplexed siRNAs, but did not show any significant inhibition of gene expression. The microscopic analysis suggested that siRNA-lipoplexes were taken up by the respective tissue, but lacked cell-specific delivery to endothelial cells. Strong fluorescence uptake might be associated with a clearance process of the siRNA-lipoplex molecules in the kidney and spleen, both important blood filters of the body.
Many human diseases aside from neo-angiogenesisdependent solid cancers, such as stroke, ulcers, atherosclerosis and rheumatoid arthritis are dependent on either excessive or insufficient angiogenesis. 50, 51 Our experimental data demonstrate that siRNA-lipoplexes enable siRNA-mediated RNAi in vascular endothelial cells, and might pave the way for the development of novel pro-and anti-angiogenic therapies. 52, 53 Future experiments will need to focus on the identification of the right targets for the specific indication, on the optimization of dosing schedules for sustained delivery and RNAi efficacy, and on the assessment of potential risk/benefit parameters.
Materials and methods
Short interfering RNAs
The siRNA molecules (AtuRNAi) used in this study are blunt, 19-mer double-stranded RNA oligonucleotides stabilized by alternating 2 0 -O-methyl modifications on both strands (for details see Czauderna et al.
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) and were synthesized by BioSpring (Frankfurt a.M., Germany). siRNA sequences used in this study are listed in Table 1 .
Preparation and characterization of siRNA-lipoplexes
Cationic liposomes comprising the novel cationic lipid b-L-arginyl-2,3-L-diaminopropionic acid-N-palmityl-Noleyl-amide trihydrochloride (AtuFECT01; Atugen AG, Berlin, Germany), the neutral/helper lipid phospholipid DPhyPE (Avanti Polar Lipids Inc., Alabaster, AL, USA) and the PEGylated lipid N-(carbonyl-methoxypolyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt (DSPE-PEG; Lipoid GmbH, Ludwigshafen, Germany) in a molar ratio of 50/49/1 were prepared by lipid film rehydration in 300 mM sterile RNase-free sucrose solution to a total lipid concentration of 4.34 mg/ml. Subsequently, the multilamellar dispersion was further processed by high-pressure homogenization (22 cycles at 750 bar and 5 cycles at 1000 bar) using an EmulsiFlex C3 device (Avestin, Inc., Ottawa, Canada). To generate siRNA-lipoplexes (AtuPLEX), the obtained liposomal dispersion was mixed with an equal volume of a 0.5625 mg/ml solution of siRNA in 300 mM sucrose, resulting in a calculated charge ratio of nucleic acid backbone phosphates to cationic lipid nitrogen atoms of approximately 1-4. The size of the liposome and the lipoplex dispersion was determined by Quasi Elastic Light Scattering (N5 Submicron Particle Size Analyzer, Beckman Coulter, Inc., Miami, FL, USA) and the zeta potential was measured using a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK).
For siRNA-lipoplex double labeling, the fluorescently labeled liposomes were generated by adding the fluorescently labeled tracer lipid TexasRed s -1,2-dihexadecanoylsn-glycero-3-phosphoethanolamine, triethylammonium salt (TexasRed s -DHPE; Molecular Probes, Eugene, OR, USA) at following ratio: 50 mol% cationic lipid (AtuFECT01)/ 44 mol% helper lipid DPhyPE/1 mol% DSPE-PEG/5 mol% TexasRed s -DHPE. The liposomes were processed by 51 extrusion cycles through a 400 nm polycarbonate membrane prior mixing resulting in a final concentration of 2.17 mg/ml total for the lipids and 0.28 mg/ml siRNA (a 200 ml injection into a 30 g mouse represents a dose of 1.88 mg/kg siRNA and 14.5 mg/kg lipid).
In vitro transfection and immunoblotting
Human HUVEC, HeLa, PC-3 as well as NIH3T3 cell lines were obtained from American Type Culture Collection and cultivated according to the ATCC's recommendation. Cell lines were transfected with siRNA using the cationic liposomes described above. Briefly, about 12 h after cell seeding different amounts of siRNA-lipoplex solution diluted in 10% serum containing medium were added to the cells to achieve transfection concentrations in a range of 1-50 nM siRNA. After transfection (48 h), cells were lysed and subjected to immunoblotting as described. 54 For total protein extraction, tissues were dissected and instantly snap-frozen in liquid nitrogen.
siRNA-lipoplex application in vivo A Santel et al Twenty milligrams of tissue were homogenized in a Mixer Mill MM 301 (Retsch GmbH, Haan, Germany) using tungsten carbide beads (Qiagen, Hilden, Germany) and proteins were extracted in NP40-lysis buffer. Protein concentration was determined with a DC Protein Assay (BioRad, Hercules, CA, USA) and equal amounts were loaded for immunobot analysis using the following antibodies: rabbit anti-PTEN (Ab-2, Neomarkers, Fremont, CA, USA), monoclonal p110a, 55 rabbit anti-PKN3, 56 goat anti-CD31 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti Tie2 (Cell Signaling Technology, Danvers, MA, USA).
Short interfering RNA-Cy3 uptake experiments in cell culture and mice
For uptake studies of non-formulated siRNA-Cy3 molecules in cell culture, cells were incubated with defined amounts of siRNA solution overnight in serum-containing medium. Uptake of lipoplexed siRNA-Cy3 was carried out by overnight transfection as mentioned above. Treated cells were rinsed with ice-cold phosphate-buffered saline (PBS) and fixed in 4% formaldehyde/PBS solution for 15 min prior to microscopy. To label late endosomes and lysosomes, cells were incubated with the fluorescent dye LysoTracker (Molecular Probes) according to the manufacturer's recommendation and examined by confocal microscopy after fixation. In vivo delivery experiment using fluorescently labeled siRNA-Cy3 was carried out by administering formulated and naked siRNA i.v. Mice were treated with a single 200 ml i.v. injection at a final dose of 1.88 mg/kg siRNACy3 and 14.5 mg/kg lipid and were killed at defined time points and fluorescence uptake examined by microscopy on either formalin-fixed, paraffin-embedded or OCT-mounted frozen tissue sections.
Histological analysis and microscopy
After mice were killed, tissues were instantly fixed in 4.5% buffered formalin for 16 h and consequently processed for paraffin embedding. 4 mm sections were cut and placed on glass slides. Tissue sections were stained with goat polyclonal anti-CD31/PECAM-1 (Santa Cruz Biotechnology) (alternatively for cryosections rat CD31, Pharmingen, San Diego, CA, USA) to visualize endothelial cells in paraffin sections. Immunohistochemistry and hematoxylin/eosin (H+E) staining on paraffin tissue sections were performed according to standard protocols. For in vivo uptake studies of fluorescently labeled siRNAs, paraffin sections were directly examined by epifluorescence with a Zeiss Axioplan microscope. Images were recorded and processed using the Zeiss LSM5 imaging software. In depth microscopic analysis of siRNA, uptake was performed with a Zeiss LSM510 Meta confocal microscope. For this, sections were deparaffinized with xylene, rehydrated through graded ethanol washes, counterstained with Sytox Green dye (Molecular Probes, 100 nM), rinsed and finally mounted in FluorSave (Calbiochem, Darmstadt, Germany) for microscopy. 0 -BHQ1. The TaqMan RT-PCR reactions were carried out with an ABI PRISM 7700 Sequence Detector (Software: Sequence Detection System v1.6.3 (ABI)) using a standard protocol for RT-PCR (481C 30 min, 951C 10 min, 40 Â (951C 15 s, 601C 1 min)) with primers at a concentration of 300 and 100 nM for the probe. TaqMan data were calculated by using the Comparative C T method. Here, the amount of target mRNA (CD31 or Tie2), normalized to an endogenous reference (CD34) and relative to a calibrator (sucrose group) is given by the formula 2 ÀDDC T . Data for individual mice are shown as C T of CD31, CD34 or Tie2 mRNA relative to sucrose presenting the mean of a triplicate7s.e.m. Data for treatment groups are shown as DDC T normalized to an endogenous reference and relative to sucrose presenting the mean of 6-8 mice per group7s.e.m.
Quantification of soluble Tie2 by enzyme-linked immunosorbent assay
For serum analysis, blood was collected from anesthetized mice by orbital sinus bleeding on days 0 and 5. Soluble Tie2 was measured by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Quantification of interleukin-12 by enzyme-linked immunosorbent assay
Male C57BL/6 mice received a single 200 ml tail-vein injection of Poly(I:C)-(Sigma, Taufkirchen, Germany) or siRNA-lipoplex solution (final dose of 1.88 mg/kg siRNA or Poly(I:C) and 14.5 mg/kg lipid). Blood was harvested from anesthetized mice by orbital sinus bleeding 2 and 24 h post-injection and serum IL-12 (p40) as well as interferon-a levels were measured by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions.
Mouse studies
Immune-deficient male Hsd:NMRI-nu/nu nude mice (9 weeks) were used for toxicity assessment of siRNAlipoplexes in vivo as well as for detection of RNAi (knockdown analysis in vivo) and Tie2 ELISA. The microscopic analysis of organ and cell type distribution of fluorescently labeled siRNA-lipoplexes, and the IL-12 ELISA analysis were carried out with immune-competent male C57BL/6 mice (8-10 weeks). The animal siRNA-lipoplex application in vivo A Santel et al maintenance and experiments were conducted according to the approved protocols and in compliance with the guidelines of the Landesamt fü r Arbeits-, Gesundheitsschutz und technische Sicherheit Berlin, Germany (No. G0264/99).
Statistical analysis
Data are expressed as means7s.e.m. Statistical significance of differences was determined by the MannWhitney U-test. P-valueso0.05 were considered statistically significant.
